[Advances in antibody-conjugating drugs in prostate cancer: applications and challenges].

In recent years, significant progress has been made in the structural optimization and mechanistic research of antibody-drug conjugates (ADC), with multiple clinical trials for prostate cancer underway and demonstrating broad clinical application prospects. Compared with traditional chemotherapy and immunotherapy, ADC combines the targeting specificity of monoclonal antibodies with the potent tumor-killing ability of chemotherapeutic drugs, offering potential therapeutic options for prostate cancer patients. Currently, four prostate-specific membrane antigen-targeted ADC have entered the clinical trial phase, but their clinical efficacy and safety profiles exhibit significant differences. Additionally, the identification of novel molecular biomarkers such as STEAP1, TROP2, and B7-H3 has provided potential targets for the development of the next generation of prostate cancer ADC, with relevant candidate drugs having progressed to clinical trials and their research outcomes highly anticipated. Although no ADC has been approved for clinical treatment of prostate cancer, in-depth analysis of the current challenges and future development directions in ADC research will provide theoretical support and innovative insights for advancing these agents in prostate cancer research.